109 related articles for article (PubMed ID: 23848940)
1. Maspin expression in the invasive margin of primary melanomas may reflect an aggressive tumor phenotype.
Pföhler C; Knöpflen T; Körner R; Vogt T; Rösch A; Müller CS
J Dtsch Dermatol Ges; 2013 Oct; 11(10):993-9. PubMed ID: 23848940
[TBL] [Abstract][Full Text] [Related]
2. Maspin expression and melanoma progression: a matter of sub-cellular localization.
Martinoli C; Gandini S; Luise C; Mazzarol G; Confalonieri S; Giuseppe Pelicci P; Testori A; Ferrucci PF
Mod Pathol; 2014 Mar; 27(3):412-9. PubMed ID: 24030740
[TBL] [Abstract][Full Text] [Related]
3. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma.
Chua R; Setzer S; Govindarajan B; Sexton D; Cohen C; Arbiser JL
J Am Acad Dermatol; 2009 May; 60(5):758-66. PubMed ID: 19389518
[TBL] [Abstract][Full Text] [Related]
4. Decreased immunoreactive maspin expression in intermediate thickness and thick primary melanoma lesions.
Vereecken P; Reynaert S; Lalmand MC; Zouaoui-Boudjeltia K; Heenen M; Van Den Heule B; Petein M
J Int Med Res; 2006; 34(1):52-7. PubMed ID: 16604823
[TBL] [Abstract][Full Text] [Related]
5. Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma.
Maelandsmo GM; Holm R; Nesland JM; Fodstad Ø; Flørenes VA
Clin Cancer Res; 2003 Aug; 9(9):3383-8. PubMed ID: 12960126
[TBL] [Abstract][Full Text] [Related]
6. Expression of maspin predicts poor prognosis in breast-cancer patients.
Umekita Y; Ohi Y; Sagara Y; Yoshida H
Int J Cancer; 2002 Aug; 100(4):452-5. PubMed ID: 12115529
[TBL] [Abstract][Full Text] [Related]
7. Loss of maspin expression contributes to a more invasive potential in malignant melanoma.
Denk AE; Bettstetter M; Wild PJ; Hoek K; Bataille F; Dietmaier W; Bosserhoff AK
Pigment Cell Res; 2007 Apr; 20(2):112-9. PubMed ID: 17371437
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
[TBL] [Abstract][Full Text] [Related]
9. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.
Friedrich MG; Toma MI; Petri S; Cheng JC; Hammerer P; Erbersdobler A; Huland H
Eur Urol; 2004 Jun; 45(6):737-43. PubMed ID: 15149745
[TBL] [Abstract][Full Text] [Related]
10. Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors.
Schwarz S; Ettl T; Kleinsasser N; Hartmann A; Reichert TE; Driemel O
Oral Oncol; 2008 Jun; 44(6):563-70. PubMed ID: 17936671
[TBL] [Abstract][Full Text] [Related]
11. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
12. Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival.
Neuber K; Eidam B
Onkologie; 2006 Sep; 29(8-9):361-5. PubMed ID: 16974112
[TBL] [Abstract][Full Text] [Related]
13. Loss of maspin is a helpful prognosticator in colorectal cancer: a tissue microarray analysis.
Boltze C
Pathol Res Pract; 2005; 200(11-12):783-90. PubMed ID: 15792121
[TBL] [Abstract][Full Text] [Related]
14. Tenascin-C in primary malignant melanoma of the skin.
Ilmonen S; Jahkola T; Turunen JP; Muhonen T; Asko-Seljavaara S
Histopathology; 2004 Oct; 45(4):405-11. PubMed ID: 15469480
[TBL] [Abstract][Full Text] [Related]
15. Nuclear Maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer.
Dietmaier W; Bettstetter M; Wild PJ; Woenckhaus M; Rümmele P; Hartmann A; Dechant S; Blaszyk H; Pauer A; Klinkhammer-Schalke M; Hofstädter F
Int J Cancer; 2006 May; 118(9):2247-54. PubMed ID: 16331619
[TBL] [Abstract][Full Text] [Related]
16. Expression of maspin in non-small-cell lung cancer: correlation with clinical features.
Takanami I; Abiko T; Koizumi S
Clin Lung Cancer; 2008 Nov; 9(6):361-6. PubMed ID: 19073519
[TBL] [Abstract][Full Text] [Related]
17. Expression of maspin in colorectal cancer.
Umekita Y; Souda M; Yoshida H
In Vivo; 2006; 20(6B):797-800. PubMed ID: 17203770
[TBL] [Abstract][Full Text] [Related]
18. eIF4E is an adverse prognostic marker of melanoma patient survival by increasing melanoma cell invasion.
Khosravi S; Tam KJ; Ardekani GS; Martinka M; McElwee KJ; Ong CJ
J Invest Dermatol; 2015 May; 135(5):1358-1367. PubMed ID: 25562667
[TBL] [Abstract][Full Text] [Related]
19. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival.
Flørenes VA; Maelandsmo GM; Kerbel RS; Slingerland JM; Nesland JM; Holm R
Am J Pathol; 1998 Jul; 153(1):305-12. PubMed ID: 9665492
[TBL] [Abstract][Full Text] [Related]
20. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
Bolat F; Gumurdulu D; Erkanli S; Kayaselcuk F; Zeren H; Ali Vardar M; Kuscu E
Pathol Res Pract; 2008; 204(6):379-87. PubMed ID: 18343598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
